Recent Updates
Recently added Catalysts

COVID-19 Vaccine

Phase 2

COVID-19 Infection | Monoclonal antibody | Oncology |GeoVax Labs, Inc.|Last Updated: Feb 10, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment63
FDA Designations
No designations recorded
Clinical trial landscape

COVID-19 Vaccine · 1 trial · 5 indications

Phase 2 1
NCT04977024SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerCOVID-19 Infection
ACTIVE NOT_RECRUITING63 Analytics
PHASE2ACTIVE NOT_RECRUITING
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
COVID-19 Infection
NCT0497702463
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
COVID-19 VaccineBIOLOGICALReceive SOC mRNA SARS-CoV-2 vaccine IM
Diagnostic Laboratory Biomarker AnalysisOTHERCorrelative studies
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1BIOLOGICALGiven IM
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT04977024studyFirstPostDate: changed